How does Verzenio (abemaciclib) work in the body?
Verzenio (abemaciclib) is a targeted cancer medicine that blocks enzymes called cyclin-dependent kinases (CDK) 4 and 6. By inhibiting CDK4/6, it interferes with cell-cycle progression—specifically the transition from the G1 phase to the S phase—so cancer cells are less able to keep dividing. [1]
What does CDK4/6 inhibition do to the cell cycle?
CDK4 and CDK6 help regulate the phosphorylation of the retinoblastoma (Rb) protein, a key step that drives the cell into DNA synthesis. When Verzenio inhibits CDK4/6, this signaling is reduced, Rb remains less phosphorylated, and the cell cycle is held back in G1, limiting proliferation. [1]
Is Verzenio’s action more about stopping growth or killing cells?
Verzenio’s primary mechanism is growth control. By blocking CDK4/6-driven cell-cycle progression, it reduces tumor cell proliferation. Its clinical effectiveness depends on how strongly a tumor’s growth is driven by the CDK4/6 pathway. [1]
How does the mechanism link to hormone receptor status?
Verzenio is used in certain hormone receptor-positive cancers where CDK4/6 signaling is a key route supporting tumor cell division. In these settings, suppressing CDK4/6 activity can make tumor growth harder to sustain. [1]
What’s the practical implication for combination therapy?
Because Verzenio targets CDK4/6 signaling, it is often paired with hormone therapy in eligible patients, aiming to attack tumor growth from two angles: hormonal signaling plus cell-cycle machinery. This strategy is based on the mechanism of CDK4/6 inhibition. [1]
Sources
[1] https://www.verzenio.com/about/verzenio-mechanism-of-action